

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.

19413

In Re Application Of: Ben Croker, et al.



Application No.	Filing Date		Customer No.	Group Art Unit	Confirmation No.
10/559,711	December 5, 2005	Unassigned	23389	Unassigned	3843

Title: METHODS OF IDENTIFYING COMPOUNDS WHICH MODULATE GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) DEPENDENT PROCESSES BY MODULATION OF THE LEVELS OF SUPPRESSOR OF CYTOKINE SIGNALING (SOCS)

Address to:
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b)(4))

Docket No.

19413

In Re Application of: Ben Croker, et al.



Application No.	Filing Date	Examiner NAME	Customer No.	Group Art Unit	Confirmation No.
10/559,711	December 5, 2005	Unsigned	23389	Unassigned	3843

Title: METHODS OF IDENTIFYING COMPOUNDS WHICH MODULATE GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) DEPENDENT PROCESSES BY MODULATION OF THE LEVELS OF SUPPRESSOR OF CYTOKINE SIGNALING (SOCS)

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.

- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

May 19, 2006

(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

Dated: May 19, 2006

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P. C.

400 Garden City Plaza-STE 300

Garden City, New York 11530

(516) 742-4343

cc: XZ:ab



10559711 *FBI* 1635

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ben Croker, et al. Examiner: Unassigned
Serial No.: 10/559,711 Art Unit: Unassigned
Filed: December 5, 2005 Docket: 19413
For: METHODS OF IDENTIFYING DATED: May 19, 2006
COMPOUNDS WHICH MODULATE
GRANULOCYTE-COLONY STIMULATING
FACTOR (G-CSF) DEPENDENT PROCESSES
BY MODULATION OF THE LEVELS OF
SUPPRESSOR OF CYTOKINE SIGNALING (SOCS)

Confirmation No.: 3843

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: May 19, 2006



Xiao Chun Zhu

1. A. Matsumoto, et al., "A Role of Suppressor of Cytokine Signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated Interleukin 2 Production", *J. Exp. Med.*, 197(4): 425-436 (2003);
2. B. A. Croker, et al., "SOCS3 negatively regulates IL-6 signaling in vivo", *Nature Immunology*, 4(6): 540-545 (2003);
3. P. Georgiades, et al., "vavCre Transgenic Mice: A Tool for Mutagenesis in Hematopoietic and Endothelial Lineages", *Genesis*, 34: 251-256 (2002);
4. M. Hörtnar, et al., "Suppressor of Cytokine Signaling-3 Is Recruited to the Activated Granulocyte-Colony Stimulating Factor Receptor and Modulates its Signal Transduction", *The Journal of Immunology*, 169: 1219-1227 (2002);
5. M. H. A. Hermans, et al., "Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid progenitor cells", *Blood*, 101(7): 2584-2590 (2003);
6. B. A. Croker, et al., "SOCS3 Is a Critical Physiological Negative Regulator of G-CSF Signaling and Emergency Granulopoiesis", *Immunity*, 20: 153-165 (2004);
7. A. Kimura, et al., "SOCS3 Is a Physiological Negative Regulator for Granulopoiesis and Granulocyte Colony-Stimulating Factor Receptor Signaling", *The Journal of Biological Chemistry*, 279(8): 6905-6910 (2004);
8. Gert-Jan M. Van de Geijn, et al., "Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling", *Journal of Leukocyte Biology*, 76: 237-244 (2004); and
9. Gert-Jan M. Van de Geijn, et al., "G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact", *Blood*, 104(3): 667-674 (2004).

The references were cited in an International Search Report dated August 26,

2004 received from the International Searching Authority. Applicants are submitting copies of the above-cited references. A copy of the Search Report was submitted by

Applicants on December 5, 2005. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Xiaochun Zhu
Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343
XZ:ab

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
(REV. 7-80) PATENT AND TRADEMARK OFFICE**LIST OF PRIOR ART
CITED BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.
19413Serial No.
10/559,711**Applicants**

Ben Croker, et al.

Filing Date

December 5, 2005

Group

Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (If appropriate)
	AA						
	AB						
	AC						

	Foreign Document Number	Date	Country	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

1.	A. Matsumoto, et al., "A Role of Suppressor of Cytokine Signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated Interleukin 2 Production", <i>J. Exp. Med.</i> , 197(4): 425-436 (2003)
2.	B. A. Croker, et al., "SOCS3 negatively regulates IL-6 signaling in vivo", <i>Nature Immunology</i> , 4(6): 540-545 (2003)
3.	P. Georgiades, et al., "vavCre Transgenic Mice: A Tool for Mutagenesis in Hematopoietic and Endothelial Lineages", <i>Genesis</i> , 34: 251-256 (2002)
4.	M. Hörtnér, et al., "Suppressor of Cytokine Signaling-3 Is Recruited to the Activated Granulocyte-Colony Stimulating Factor Receptor and Modulates its Signal Transduction", <i>The Journal of Immunology</i> , 169: 1219-1227 (2002)
5.	M. H. A. Hermans, et al., "Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid progenitor cells", <i>Blood</i> , 101(7): 2584-2590 (2003)
6.	B. A. Croker, et al., "SOCS3 Is a Critical Physiological Negative Regulator of G-CSF Signaling and Emergency Granulopoiesis", <i>Immunity</i> , 20: 153-165 (2004)
7.	A. Kimura, et al., "SOCS3 Is a Physiological Negative Regulator for Granulopoiesis and Granulocyte Colony-Stimulating Factor Receptor Signaling", <i>The Journal of Biological Chemistry</i> , 279(8): 6905-6910 (2004)
8.	Gert-Jan M. Van de Geijn, et al., "Distinct activities of suppressor of cytokine signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling", <i>Journal of Leukocyte Biology</i> , 76: 237-244 (2004)
9.	Gert-Jan M. Van de Geijn, et al., "G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3 intact", <i>Blood</i> , 104(3): 667-674 (2004)

EXAMINER

/Dana Shin/

DATE CONSIDERED

06/16/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/